Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial. // The Lancet Respiratory Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S221326002600192X?dgcid=rss_sd_all
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial. The Lancet Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S221326002600192X?dgcid=rss_sd_all
“Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial.” The Lancet Respiratory Medicine.
@article{article32489,
title = {Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial},
journal = {The Lancet Respiratory Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S221326002600192X?dgcid=rss_sd_all}
}